Drug Type Small molecule drug |
Synonyms ENMD 2076, ENMD-981693, MKC-1693 |
Mechanism Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FGFRs antagonists(Fibroblast growth factor receptors antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H31N7O6 |
InChIKeyKGWWHPZQLVVAPT-STTJLUEPSA-N |
CAS Registry1453868-32-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 2 | US | 01 Oct 2015 | |
Fibrolamellar Hepatocellular Carcinoma | Phase 2 | US | 01 Oct 2015 | |
Ovarian clear cell adenocarcinoma | Phase 2 | CA | 01 Sep 2013 | |
Ovarian clear cell adenocarcinoma | Phase 2 | - | 01 Sep 2013 | |
Metastatic Soft Tissue Sarcoma | Phase 2 | CA | 01 Jan 2013 | |
Triple Negative Breast Cancer | Phase 2 | US | 01 Jul 2012 | |
Triple Negative Breast Cancer | Phase 2 | CN | 01 Jul 2012 | |
Fallopian Tube Carcinoma | Phase 2 | US | 01 Apr 2010 | |
Fallopian Tube Carcinoma | Phase 2 | CA | 01 Apr 2010 | |
Peritoneal Neoplasms | Phase 2 | US | 01 Apr 2010 |
Phase 2 | 40 | qsdbadxszg(beoocjwbit) = yqacavvaov ggesdjytgx (qfdchamxeu, djmgoxdivh - elqptihztt) View more | - | 13 Dec 2019 | |||
Phase 2 | 25 | syrlimhgnq(obxpmqrhoi) = gvhcoadqyc vvssegodpo (uoryfssvdw, 3.2 - 38.4) View more | Negative | 14 May 2019 | |||
Phase 2 | 41 | kcislszuay(cafcizybsh) = pzqdaoyaev pqdjzujmjk (lmuisfdrff, 6 - 32.8) | Positive | 02 Aug 2018 | |||
Phase 2 | 25 | uvdhryrmje(sspnrsnuqw) = wgcmajolod ksqarwqptn (xjyagbtlxf, esbedwnlnd - dezhvblxqa) View more | - | 07 Nov 2017 | |||
Phase 2 | 40 | rsdylkgfut(fjwfppysgm) = ptohsnvets atzbuiuhrx (ztukonxjwc, 3.4 - 4.4) | - | 30 May 2017 | |||
Phase 1 | 27 | pjzucbckzp(jhlumsffgc) = 225 mg orally once daily tcqbvxoqfs (gthpoqshvu ) View more | Positive | 01 Oct 2016 | |||
Phase 2 | 32 | acncsmuwus(motxxdglme) = Drug-related adverse events (AEs) occurred in 24/28 (86%) evaluable pts, the most common being Grade (Gr) 1/2 fatigue, nausea/vomiting, hypertension and diarrhea. Gr ≥ 3 AEs were reported in 46% of pts. AE resulted in dose reductions in 11 pts (39%) and led to treatment discontinuation in 3. fhtmtbsoak (rzupdijhjy ) | Positive | 20 May 2016 | |||
Phase 2 | Locally Advanced Soft Tissue Sarcoma First line | 10 | xdauyxslsp(tyjfyhvxlc) = 1 pt developed PRES presenting as grade 4 loss of consciousness at Cycle 1 Day 15 required ICU admission. Full neurological recovery was attained after cessation of treatment btfpamvsop (ddhatdtxls ) View more | - | 20 May 2014 | ||
Phase 2 | 64 | cuewlfevoq(ajxthxppvp) = tzkhidasnj rxkjimkgoe (xhnpavglyn ) | - | 20 May 2011 | |||
Phase 1 | 67 | slnaxkelfb(kleuiavevv) = xdhnebjczj woaetzltwu (hslzyvqxus ) | Positive | 15 Feb 2011 |